The Kendall Square Association (KSA) was founded in 2009 on the idea that while we go faster alone, we go further together. Through its convening power and vital programming, the KSA advances Kendall Square’s vibrant innovation ecosystem. What was once an industrial rail yard has now become the most innovative square mile on the planet.

The unique collection of, and collaboration between, life-science, technology, community, and research institutions that make up the KSA’s membership is what enabled a rapid response to the COVID-19 pandemic, both globally with vaccine development and locally with fast, accurate, equitable, and affordable testing. 

Innovation that benefits patients requires impactful partnerships between public and private entities and the communities we serve. This is why, like many other organizations in Cambridge and across the country, we were concerned by the April 7 decision by the Centers for Medicare and Medicaid Services (CMS) to limit coverage of Alzheimer’s drug Aduhelm, which had previously been approved by the Food and Drug Administration (FDA). 

In fields where new options for patients are critical, innovation is essential. We believe the FDA and CMS should center around health equity and access, allowing continued innovation through its processes and decisions, to have a tremendous impact on the lives of patients.